Stockscreener 앱 받기
31.22
2.59%
-0.83
전일 마감가:
$32.05
열려 있는:
$31.98
하루 거래량:
1.61M
Relative Volume:
0.77
시가총액:
$3.17B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-17.25
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
+13.32%
1개월 성능:
+16.67%
6개월 성능:
+55.56%
1년 성능:
+33.42%
1일 변동 폭
$30.78
$32.24
1주일 범위
$29.16
$36.44
52주 변동 폭
$13.53
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
31.22 | 3.25B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1%Should You Sell? - MarketBeat
Earnings Report: Is Beam Therapeutics Inc a cyclical or defensive stock2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Intraday: What is Rapid7 Incs 5 year growth outlookPortfolio Return Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com
Gene editing trials in sickle cell advance as Beam builds $1.1B cash - Stock Titan
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Bernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM: Base editing programs advance toward approval, backed by strong data, funding, and scalable technology - TradingView — Track All Markets
BEAM: Predictable gene editing advances drive pivotal programs and commercial readiness into 2029 - TradingView — Track All Markets
Buyback Watch: How does AHTPRI score in quality rankingsQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - sharewise.com
Beam Therapeutics: Pivoting From Platform To Execution Stage (NASDAQ:BEAM) - Seeking Alpha
April 17th Options Now Available For Beam Therapeutics - Nasdaq
Beam Therapeutics (BEAM) to Submit Biologics License Application for Risto-cel by End of 2026 - Intellectia AI
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 - Yahoo Finance
Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally - TechStock²
Beam Therapeutics Price Target Upgrade Signals Positive Outlook - timothysykes.com
Gene Editor Soars To 10-Month High On Bullish FDA News - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpTime to Buy? - MarketBeat
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Key facts: Beam Therapeutics seeks FDA approval for BEAM-302 therapy - TradingView — Track All Markets
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? - Benzinga
Beam Therapeutics (BEAM) Shares Surge Nearly 28% - GuruFocus
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise - Stocktwits
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Beam Therapeutics (BEAM) Sees Positive Developments in Regulator - GuruFocus
Beam Therapeutics higher after reaching FDA alignment on BEAM-302 - TipRanks
Beam Therapeutics (BEAM) Eyes Accelerated FDA Approval for BEAM-302 - GuruFocus
Beam Therapeutics (BEAM) Shares Soar on Strategic Advances - GuruFocus
Beam Therapeutics (BEAM) Shares Surge Over 23% in Recent Trading - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $37 on AATD program outlook - Investing.com Australia
Why Beam Therapeutics Stock Is Sliding Despite Progress - TipRanks
Beam Therapeutics outlines 2026 strategy and extends runway - TipRanks
Beam Therapeutics To Report BEAM-302 Trial Data In Q1; Submit Risto-cel BLA By Year-End 2026 - Nasdaq
Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises - marketscreener.com
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition - GlobeNewswire
Beam Therapeutics (NASDAQ:BEAM) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Analyst Calls: Will Beam Therapeutics Inc. stock benefit from infrastructure spendingTreasury Yields & Free Community Supported Trade Ideas - ulpravda.ru
Will Beam Therapeutics Inc. stock reach all time highs in 2025Treasury Yields & Proven Capital Preservation Methods - Улправда
Behavioral Patterns of BEAM and Institutional Flows - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at UBS Group - MarketBeat
What catalysts could drive Beam Therapeutics Inc. stock higherGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Will Beam Therapeutics Inc. stock beat EPS estimatesMarket Risk Summary & Weekly Watchlist for Consistent Profits - ulpravda.ru
What dividend safety score for Beam Therapeutics Inc. stock2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
How resilient is Beam Therapeutics Inc. stock in market downturnsWatch List & Low Drawdown Momentum Ideas - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Bank of America Securities Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
Does ARK’s BEAM (BEAM) Buying and Regulatory Momentum Reinforce the Bull Case for Base Editing? - simplywall.st
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Emany Sravan Kumar | Chief Financial Officer |
Dec 31 '25 |
Sale |
27.10 |
6,294 |
170,567 |
73,706 |
| Bellon Christine | Chief Legal Officer |
Dec 31 '25 |
Sale |
27.10 |
1,254 |
33,983 |
115,667 |
| FMR LLC | See Remark 1 |
Oct 27 '25 |
Sale |
26.68 |
459 |
12,246 |
14 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
4.73%
0.92%
자본화:
|
볼륨(24시간):